Exchange Traded Concepts LLC Sells 24,064 Shares of CareDx, Inc (NASDAQ:CDNA)

Exchange Traded Concepts LLC lowered its stake in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 46.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,291 shares of the company's stock after selling 24,064 shares during the period. Exchange Traded Concepts LLC owned about 0.05% of CareDx worth $852,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC grew its holdings in shares of CareDx by 9.2% during the first quarter. Los Angeles Capital Management LLC now owns 259,007 shares of the company's stock worth $2,743,000 after buying an additional 21,892 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of CareDx by 10,267.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company's stock valued at $198,000 after buying an additional 18,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of CareDx by 87.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 228,198 shares of the company's stock worth $2,417,000 after purchasing an additional 106,660 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in CareDx in the 1st quarter worth $238,000. Finally, Russell Investments Group Ltd. raised its position in shares of CareDx by 35.0% in the 1st quarter. Russell Investments Group Ltd. now owns 122,227 shares of the company's stock valued at $1,294,000 after purchasing an additional 31,667 shares in the last quarter.

CareDx Trading Down 2.0 %

NASDAQ CDNA traded down $0.50 on Friday, reaching $23.98. The company's stock had a trading volume of 1,507,520 shares, compared to its average volume of 911,372. CareDx, Inc has a 52 week low of $4.80 and a 52 week high of $34.84. The firm has a market cap of $1.25 billion, a PE ratio of -7.01 and a beta of 1.77. The business has a 50-day moving average price of $29.62 and a 200 day moving average price of $19.64.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.37. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. The business had revenue of $92.27 million during the quarter, compared to the consensus estimate of $67.20 million. Analysts anticipate that CareDx, Inc will post -0.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CDNA shares. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a report on Thursday. The Goldman Sachs Group increased their price target on CareDx from $26.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday. BTIG Research upgraded shares of CareDx from a "neutral" rating to a "buy" rating and set a $40.00 price objective on the stock in a research note on Monday, August 19th. Craig Hallum upped their price target on shares of CareDx from $22.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, August 1st. Finally, Wells Fargo & Company started coverage on CareDx in a report on Tuesday, August 27th. They issued an "underweight" rating and a $28.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $30.60.

Insider Buying and Selling

In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of the business's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $33.55, for a total value of $1,148,450.05. Following the transaction, the insider now directly owns 284,983 shares in the company, valued at $9,561,179.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Peter Maag sold 35,552 shares of the firm's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the transaction, the director now owns 330,024 shares in the company, valued at $10,903,992.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander L. Johnson sold 34,231 shares of CareDx stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $33.55, for a total value of $1,148,450.05. Following the completion of the sale, the insider now owns 284,983 shares of the company's stock, valued at approximately $9,561,179.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock worth $3,025,415 in the last quarter. 4.20% of the stock is owned by corporate insiders.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.